Care for children with achondroplasia in Germany – current status and future implications
Achondroplasia is one of the most prevalent skeletal dysplasia. It is caused by a gain-of-function mutation in the FGFR3 gene, leading to impaired longitudinal growth of bones, resulting in disproportionate short stature with rhizomelic limb shortening, and possible life-threatening systemic complications in infancy associated with foramen magnum stenosis and sleep apnea. The aim of this position statement was to obtain an overview of medical care of children with achondroplasia in Germany and compare it to recent international guidelines. In order to assess achondroplasia management in children, a panel of twelve pediatric experts from specialized German centers formulated statements on 39 predefined questions. Through moderated online discussion and virtual meetings, key aspects of diagnosis, management, treatment, and care pathways were analyzed and this position statement on the German status quo was developed. Achondroplasia care in Germany is provided by centralized, multidisciplinary structures, predominantly located in specialized centers. However, depending on the location of the center, access to care often requires long travel distances for the families. Regarding diagnosis, first visit and follow-up examinations, international guidelines are generally followed. Nevertheless, there is variability in timing of referral and follow-up schedules, reflecting the different approaches of the centers. Standardized transition processes from pediatric to adult care are universally lacking, representing room for improvement in this area to enable further specialized care in adulthood. Following approval of the first targeted pharmacological treatment to promote growth in achondroplasia in September 2021, care structures and options for achondroplasia treatment have changed significantly. Vosoritide, a peptide analog that inhibits downstream signaling of constitutively active FGFR3, is now widely used in accordance with national approval.
Authors
- Tilman Robert Rohrer (ORCID: https://orcid.org/0000-0001-9516-7863)
- Susanna Reincke (ORCID: https://orcid.org/0000-0003-2286-5761)
- Stefanie Groß (ORCID: https://orcid.org/0000-0002-5406-1736)
- Peter Freisinger (ORCID: https://orcid.org/0000-0003-1675-9372)
- Katja Wechsung (ORCID: https://orcid.org/0000-0001-5494-3328)
- Oliver Semler (ORCID: https://orcid.org/0000-0003-0029-7556)
- Katja Palm (ORCID: https://orcid.org/0000-0003-4383-266X)
- Monika Flury (ORCID: https://orcid.org/0009-0009-6175-9866)
- Maesa Al-Hallak
- Dorna Hogeabri
- Ekkehart Lausch
- Ann-Kathrin Blume
- Joachim Woelfle
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1186/s13023-026-04498-w
- Primary Topic
- Connective tissue disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00